A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors - Full Text View

Sponsored by:	Pfizer
Information provided by:	Pfizer
ClinicalTrials.gov Identifier:	NCT00528619

Purpose

This study will assess the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin in patients with advanced solid tumors.

Condition	Intervention	Phase
Mesothelioma Non-Small Cell Lung Cancer Neoplasms	Drug: Sunitinib, Pemetrexed, Cisplatin, Carboplatin	Phase I

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study
Official Title:	Phase I Study Of SU011248 In Combination With Pemetrexed, Pemetrexed/Cisplatin And Pemetrexed/Carboplatin In Patients With Advanced Solid Malignancies

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer Mesothelioma

Drug Information available for: Cisplatin Carboplatin Pemetrexed Pemetrexed disodium Sunitinib malate Sunitinib

U.S. FDA Resources

Further study details as provided by Pfizer:

Primary Outcome Measures:

To determine maximally tolerated dose of SU011248 (dosed continuously or on a 2/1 Schedule) when given in combination with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin. [ Time Frame: From screening until at least 28 days beyond discontinuation of study treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

To evaluate the plasma pharmacokinetics of SU011248 and its metabolite, SU012662 in addition to pemetrexed, SU011248 and pemetrexed/cisplatin, and SU011248 and pemetrexed/carboplatin when these drugs are co-administered. [ Time Frame: From screening until disease progression or discontinuation of the study ] [ Designated as safety issue: No ]
To preliminarily assess the antitumor activity of SU011248 in addition to pemetrexed, SU011248 and pemetrexed/cisplatin, and SU011248 and pemetrexed/carboplatin in patients with non-small cell lung cancer or advanced unresectable mesothelioma. [ Time Frame: From screening until disease progression or discontinuation of the study ] [ Designated as safety issue: No ]

Estimated Enrollment:	100
Study Start Date:	November 2006
Estimated Study Completion Date:	March 2010
Estimated Primary Completion Date:	March 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
A: Experimental	Drug: Sunitinib, Pemetrexed, Cisplatin, Carboplatin Dose finding study using Sunitinib daily by oral capsule in a continuous regimen or administered for 2 weeks out of every 3 weeks, with pemetrexed every 3 weeks or also with cisplatin 75 mg/m2 or carboplatin AUC=5 mg*min/mL until progression or unacceptable toxicity.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with a diagnosis of a solid cancer which is not responsive to standard therapy or for which no standard therapy exists.
Patient has a good performance status (ECOG 0 or 1).

Exclusion Criteria:

Prior treatment with either pemetrexed or SU011248.
Coughing up blood within 4 weeks before starting study treatment (small amounts okay).
Hypertension that cannot be controlled by medications.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00528619

Contacts

Contact: Pfizer Oncology Clinical Trial Information Service	1-877-369-9753	PfizerCancerTrials@emergingmed.com
Contact: Pfizer CT.gov Call Center	1-800-718-1021

Locations

United States, Colorado
Pfizer Investigational Site	Recruiting
Aurora, Colorado, United States, 80012
Pfizer Investigational Site	Recruiting
Aurora, Colorado, United States, 80045
Pfizer Investigational Site	Recruiting
Denver, Colorado, United States, 80218
Canada, Ontario
Pfizer Investigational Site	Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Canada, Quebec
Pfizer Investigational Site	Recruiting
Montreal, Quebec, Canada, H2L 4M1

Sponsors and Collaborators

Pfizer

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

Additional Information:

To obtain contact information for a study center near you, click here. This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Pfizer Inc ( Director, Clinical Trial Disclosure Group )
Study ID Numbers:	A6181084
Study First Received:	September 10, 2007
Last Updated:	June 21, 2009
ClinicalTrials.gov Identifier:	NCT00528619 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Pfizer:

Solid tumor malignancy, non-small cell lung cancer, sunitinib, pemetrexed, Phase 1

Study placed in the following topic categories:

Antimetabolites
Thoracic Neoplasms
Folate
Carboplatin
Folinic Acid
Folic Acid Antagonists
Angiogenesis Inhibitors
Vitamin B9
Carcinoma
Folic Acid
Pemetrexed

Radiation-Sensitizing Agents
Cisplatin
Respiratory Tract Diseases
Lung Neoplasms
Sunitinib
Lung Diseases
Mesothelioma
Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Adenoma
Neoplasms, Glandular and Epithelial

Additional relevant MeSH terms:

Antimetabolites
Thoracic Neoplasms
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Neoplasms, Mesothelial
Antineoplastic Agents
Physiological Effects of Drugs
Neoplasms by Site
Respiratory Tract Diseases
Cisplatin
Lung Neoplasms
Sunitinib
Therapeutic Uses
Growth Inhibitors
Angiogenesis Modulating Agents

Respiratory Tract Neoplasms
Neoplasms by Histologic Type
Growth Substances
Enzyme Inhibitors
Carboplatin
Folic Acid Antagonists
Angiogenesis Inhibitors
Pharmacologic Actions
Carcinoma
Pemetrexed
Neoplasms
Radiation-Sensitizing Agents
Lung Diseases
Mesothelioma
Adenoma

ClinicalTrials.gov processed this record on July 02, 2009